Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by MADDEN SECURITIES Corp

MADDEN SECURITIES Corp lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 32.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,155 shares of the biopharmaceutical company's stock after selling 4,345 shares during the quarter. MADDEN SECURITIES Corp's holdings in Gilead Sciences were worth $1,026,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of GILD. Newbridge Financial Services Group Inc. acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $33,000. Annis Gardner Whiting Capital Advisors LLC increased its holdings in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 216 shares during the last quarter. Morton Brown Family Wealth LLC bought a new stake in Gilead Sciences during the fourth quarter worth $35,000. Whipplewood Advisors LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at $35,000. Finally, Synergy Investment Management LLC bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $40,000. Institutional investors own 83.67% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GILD. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Cantor Fitzgerald started coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. BMO Capital Markets raised their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Finally, Bank of America upped their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Trading Down 2.6%

GILD traded down $2.91 during trading on Tuesday, hitting $110.09. 8,870,755 shares of the stock were exchanged, compared to its average volume of 7,749,498. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a 50 day simple moving average of $105.41 and a 200 day simple moving average of $101.80. The firm has a market cap of $136.94 billion, a price-to-earnings ratio of 297.54, a P/E/G ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 1 year low of $62.69 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business's revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.32) EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares of the company's stock, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the transaction, the chief financial officer now directly owns 165,674 shares in the company, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,000 shares of company stock valued at $4,630,310. Company insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.